8T8 Stock Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TransMedics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.14 |
| 52 Week High | US$90.50 |
| 52 Week Low | US$41.22 |
| Beta | 1.98 |
| 1 Month Change | 33.04% |
| 3 Month Change | n/a |
| 1 Year Change | 30.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8T8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 1.1% |
| 1Y | 30.6% | -8.5% | 1.9% |
Return vs Industry: 8T8 exceeded the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 8T8 exceeded the German Market which returned 1.9% over the past year.
Price Volatility
| 8T8 volatility | |
|---|---|
| 8T8 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8T8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8T8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 584 | Waleed Hassanein | www.transmedics.com |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
TransMedics Group, Inc. Fundamentals Summary
| 8T8 fundamental statistics | |
|---|---|
| Market cap | €2.98b |
| Earnings (TTM) | -€23.38m |
| Revenue (TTM) | €225.70m |
13.2x
P/S Ratio-127.6x
P/E RatioIs 8T8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8T8 income statement (TTM) | |
|---|---|
| Revenue | US$241.62m |
| Cost of Revenue | US$87.53m |
| Gross Profit | US$154.09m |
| Other Expenses | US$179.12m |
| Earnings | -US$25.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 63.77% |
| Net Profit Margin | -10.36% |
| Debt/Equity Ratio | 368.9% |
How did 8T8 perform over the long term?
See historical performance and comparison